Integrum terminates agreement with Redeye regarding equity research coverage

Mölndal, Sweden, June 16, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has terminated the agreement with Redeye regarding equity research coverage.

Redeye will continue to cover Integrum until the agreement expires on December 11, 2025.

Integrum retains the commissioned research from DNB Carnegie: Integrum - Carnegie  

For more information, please contact:
Martin Hillsten, CEO
Tel: +46 733 55 28 32
Email: martin.hillsten@integrum.se

Certified Adviser
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.

About integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.